GGrantIndex
Sort

64,565 grants matching drug discovery

CHEMICAL GENETIC APPROACHES TO BASIC CELL BIOLOGY

$1,419,990
Harvard University (Medical School) · P01 · FY2001 · GM

1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)

$1,419,180
Joseph Eric Levitt · Stanford University · UG3 · FY2019 · HL

Molecular diagnosis and outcome prediction in lymphoma

$1,418,557
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

High Throughput Screening for Ligands for Seven Transmembrane-spanning Receptors

$1,417,665
Marvin Gershengorn · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK

Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease

$1,417,658
Scott Scarneo · Eydis Bio, Inc. · R44 · FY2025 · HL

Discovery of Anticancer Agents of Diverse Natural Origin

$1,417,476
Alan Douglas Kinghorn · Ohio State University · P01 · FY2015 · CA

AMP-AD Data Coordination Center

$1,417,076
Lara M Mangravite · Sage Bionetworks · U24 · FY2020 · AG

Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center

$1,416,000
Mustafa None Sahin · Boston Children'S Hospital · P50 · FY2025 · HD

Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center

$1,416,000
Mustafa None Sahin · Boston Children'S Hospital · P50 · FY2024 · HD

Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center

$1,416,000
Mustafa None Sahin · Boston Children'S Hospital · P50 · FY2022 · HD

Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center

$1,416,000
Mustafa None Sahin · Boston Children'S Hospital · P50 · FY2023 · HD

Activity-dependent probes for spatially-defined proteomics

$1,414,340
Christina Kim · University Of California At Davis · DP2 · FY2023 · MH

Regulatory landscape of the human genome: comparative and evolutionary analysis.

$1,414,230
Ivan Ovcharenko · National Library Of Medicine · ZIA · FY2014 · LM

Pathogen-specific drug targets for weaponized bacteria

$1,413,978
Vincent A. Fischetti · Rockefeller University · U19 · FY2006 · AI

Vascular remodeling in patients with rare genetic disorders

$1,413,751
Manfred Boehm · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL

Lung-on-a-Chip Disease Models for Efficacy Testing

$1,413,750
Donald E Ingber · Harvard University · UH3 · FY2019 · HL

Lung-on-a-Chip Disease Models for Efficacy Testing

$1,413,750
Donald E Ingber · Harvard University · UH3 · FY2021 · HL

Lung-on-a-Chip Disease Models for Efficacy Testing

$1,413,750
Donald E Ingber · Harvard University · UG3 · FY2017 · HL

Lung-on-a-Chip Disease Models for Efficacy Testing

$1,413,750
Donald E Ingber · Harvard University · UH3 · FY2020 · HL

MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS

$1,413,657
Matthew J Ellis · Baylor College Of Medicine · U01 · FY2018 · CA

A Quantitative Proteomics Platform to Characterize the Nicotine-Dependent Brain

$1,413,284
Benjamin F Cravatt · Scripps Research Institute, The · RC2 · FY2010 · DA

Automation and validation of human on a chip systems for drug discovery

$1,412,888
Michael L Shuler · Hesperos, Llc · R44 · FY2019 · TR

Pathogen-specific drug targets for weaponized bacteria

$1,412,862
Vincent A. Fischetti · Rockefeller University · U19 · FY2007 · AI

Texas Repository for AIDS Neuropathogenesis Research

$1,412,231
Benjamin B. Gelman · University Of Texas Med Br Galveston · R24 · FY2007 · NS

Next generation T cell therapies for mutant KRAS solid tumors

$1,412,213
Beatriz M. Carreno · University Of Pennsylvania · UG3 · FY2024 · CA